Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry

Andrea Surcinelli, Tomas Kalincik, Izanne Roos, Emanuele D, Jeannette Lechner-Scott, Serkan Ozakbas, Pavel Hradilek, Dana Horáková, Marta Vachova, Ivan Panzera, Stefano Ruzza, Maria Grazia Piscaglia, Oliver Gerlach, Jose Eustasio Meca-Lallana, Gabriel Valero-López, Allan G. Kermode, Marzena J. Fabis-Pedrini, Julie Prevost, Radek Ampapa, Suzanne Hodgkinson, Francois Grand, Samia J. Khoury, Nevin A John, Marek Peterka, Jana Houskova, Eva Recmanova, Zuzana Rous, Vahid Shaygannejad, Raed Alroughani, Jens Kuhle, Gregor Brecl Jakob, Pierre Grammond, Francesco Patti, Anneke Van der Walt, Helmut Butzkueven, Matteo Foschion behalf of the MSBase Study Group

Therapeutic Advances in Neurological Disorders

Published online on March 27, 2026

Abstract

Therapeutic Advances in Neurological Disorders, Volume 19, January-December 2026.
Background:Late-onset multiple sclerosis (LOMS), defined by symptom onset after age 50, is increasingly recognised as a distinct clinical entity. Evidence comparing disease-modifying therapies (DMTs) in this subgroup remains limited.Objectives:To compare ...